FDA pre-submission package to pursue human clinical trials with the goal of bringing this life-saving technology to the market." Once the pre-clinical study and requisite benchtop testing are successfully completed, we plan to file a U.S. This priority initiative continues to advance, benefitting from more than $11M in government contracts. Vincent Capponi, President and Chief Operating Officer of CytoSorbents indicated, "Our HemoDefend-BGA program has the potential to address a global need for universal plasma in both civilian and combat casualty care. We are excited to begin this portion of the development program." Through prior awards, we have worked to optimize the efficiency, robustness, and form factor of our HemoDefend-BGA adsorber, and look forward to taking what we believe is a transformative technology into large animal testing, where we will evaluate the safety and efficacy of universal plasma generated by HemoDefend-BGA. Army will be used to complete the development of our anti-A and anti-B blood group antibody reduction technology. Maryann Gruda, Principal Investigator and Senior Director of Biology at CytoSorbents stated, "This funding from the U.S. Without the need for blood typing, widespread availability of universal plasma could help save lives via faster emergency treatment in both civilian and military settings.ĭr. The HemoDefend-BGA adsorber can rapidly remove >99% of anti-A and anti-B antibodies from plasma to create a "universal plasma" that could be administered to anyone, irrespective of blood type, while maintaining critical coagulation activity. CytoSorbents' HemoDefend-BGA program has the potential to address a global need for universal plasma in critical illness
0 kommentar(er)
